X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

Japan Approves Daiichi Sankyo Blood Cancer Drug Ezharmia

Content Team by Content Team
30th September 2022
in FDA Approvals, News

Daiichi Sankyo, a Japanese company, has been concentrating on a series of antibody-drug conjugates, but it has achieved a world first in a field that Pfizer is also pursuing. The Japanese government has given Daiichi Sankyo permission to use Ezharmia, also known as valemetostat (DS-3201), to treat adult T-cell leukaemia or lymphoma (ATL) that has relapsed or become resistant to treatment.

According to Wataru Takasaki, Ph.D., head of Daiichi’s Japan R&D, Ezharmia is now the first EZH1/2 dual inhibitor to get authorization anywhere in the world as a result of the approval.

Epizyme’s Tazverik received authorization for epithelioid sarcoma in 2020, making it the first EZH2 inhibitor to receive FDA approval. Tazverik generated $8.9 million in commercial sales in the second quarter following an additional 2020 approval in follicular lymphoma. For about $247 million, Epizyme recently sold itself to Ipsen.

Along with Epizyme, Pfizer recently revealed preliminary results for its investigational EZH2 candidate, PF-06821497, in prostate cancer and follicular lymphoma.

The weakness of EZH2 blocking alone, according to Daiichi’s worldwide R&D leader Ken Takeshita, M.D., may be addressed by a combination of EZH1 and EZH2 inhibition, he said during an investor event in December. The fact that Ezharmia has demonstrated efficacy in both T- and B-cell lymphomas distinguishes it from other treatments that can only reach one form of lymphoma, he continued.

Based on a single-arm phase 2 experiment involving only 25 Japanese patients with three different subtypes of ATL, Japan’s health officials approved Ezharmia. In 48% of patients, including 20% of those who showed no signs of malignancy following therapy, the medication reduced tumour size. According to Daiichi, there are only approximately 3,000 new diagnoses of ATL each year, with 1,000 of those cases occurring in Japan.

In contrast, Daiichi is aiming for a larger market in both its geographic scope and its indications. The company is testing Ezharmia for clinically diagnosed peripheral T-cell lymphoma, including ATL, in the Valentine-PTCL01 global registrational phase 2 research.

According to Takeshita’s presentation in December, Daiichi is working with a French research team on a phase 2 study in individuals with six subtypes of refractory or relapsed B-cell lymphoma for the considerably bigger B-cell lymphoma area.

When Daiichi’s quizartinib, which is marketed in Japan as Vanflyta, was rejected by the FDA in 2019, the company’s blood cancer drug portfolio suffered. Daiichi is aiming for international applications for the medicine in newly diagnosed acute myeloid leukaemia with the FLT3-ITD mutation, including in the U.S. and EU, armed with new patient survival data.

And currently, a lot of Daiichi’s focus is on the antibody-drug conjugate platform, which is headed by the HER2-targeted treatment Enhertu, a collaboration with AstraZeneca. By the end of its fiscal year in 2025, Daiichi said in its new five-year plan, it hopes to generate JPY 1.6 trillion ($11.1 billion) in income, of which JPY 600 billion ($4.2 billion) will come from cancer medications.

Previous Post

Alzheimers Medicine Change Helped Biden Win Medicare Costs

Next Post

Roche Pays $70M To Close The Gap On Cancer Cell Treatments

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post
Roche receives FDA approval for expanded use of the CINtec PLUS Cytology test to aid clinicians in preventing cervical cancer

Roche Pays $70M To Close The Gap On Cancer Cell Treatments

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In